Trial
NCT06681766
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Larimar Therapeutics, Inc.
Collaborators
—
Condition
Friedreich Ataxia
Intervention
Nomlabofusp
Why stopped
Review of Cohort 1 data facilitated direct enrollment into open label study and eliminate pause in study drug administration between PK study and open label study.
Provenance
Dataset: 2026-07-10 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-10